Side-by-side comparison of AI visibility scores, market position, and capabilities
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Merged with PatientPop → Tebra 2021; $222M funding; $1B+ valuation; $72M 2023 (Golub); 100K providers; 90M patients; 1,000 employees; practice management/EHR leader
Kareo was founded in 2004 by Dan Rodrigues to build purpose-designed practice management and billing software for independent physician practices — a segment underserved by legacy healthcare IT vendors focused on hospital systems. The platform addressed the full administrative workflow of a small medical practice: appointment scheduling, patient registration, insurance eligibility verification, charge capture, medical billing, and accounts receivable management. Kareo also developed an integrated EHR module, making it one of the few vendors to combine clinical documentation and practice management in a cloud-native platform accessible to solo practitioners.\n\nKareo's products included Kareo Billing for RCM, Kareo Clinical for EHR and documentation, and Kareo Engage for patient communication and online reputation management. The platform served primary care, mental health, physical therapy, and chiropractic specialties. Its cloud-based delivery — accessible via browser and mobile without on-premises infrastructure — resonated strongly with independent practices managing lean overhead. A managed RCM service and QuickBooks integration rounded out the offering.\n\nKareo merged with PatientPop, a digital practice growth platform, in 2021 to form Tebra — targeting the full lifecycle of independent practice management from marketing through billing. The combined company has raised $222 million in total funding, achieved a $1 billion+ valuation, and serves over 100,000 providers across 90 million patients. Tebra continues operating the Kareo brand for billing and EHR while integrating PatientPop's digital presence capabilities into a unified independent practice growth platform.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.